𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Design of superactive and selective integrin receptor antagonists containing the RGD sequence

✍ Scribed by Horst Kessler; Beate Diefenbach; Dirk Finsinger; Armin Geyer; Marion Gurrath; Simon L. Goodman; Günter Hölzemann; Roland Haubner; Alfred Jonczyk; Gerhard Müller; Erich Graf Roedern; Jochen Wermuth


Book ID
104628403
Publisher
Springer Netherlands
Year
1995
Tongue
English
Weight
379 KB
Volume
2
Category
Article
ISSN
1573-3149

No coin nor oath required. For personal study only.

✦ Synopsis


Integrins play a major role in cell-cell and cell-matrix interactions. The majority of the different types of integrins recognize the tripeptide sequence arginine-glycine-aspartic acid (RGD). To explore the spatial requirements of the pharmacophore for receptor selectivity and high activity, a new procedure, 'spatial screening', was used. The procedure is based on the experience that the conformation of small cyclic peptides is mainly determined by the chirality of the amino acids (and glycine or proline). For example, cyclic pentapeptides with one D and four L amino acids prefer a 13II'/~/conformation. The sequence RGDFV was shifted around this spatial I~II'/y template by synthesis of five peptides in which one of the amino acids was used in D-configuration. It turned out that cyclo(-RGDfV-) is a selective inhibitor for the %[33 integrin, which is strongly expressed in cancer cells. Systematic variations with different turn mimetics, retro-inverso structures, modified peptide bonds and sugar amino acids are discussed.


📜 SIMILAR VOLUMES


Rational Design of Highly Active and Sel
✍ Dominik Heckmann; Axel Meyer; Burkhardt Laufer; Grit Zahn; Roland Stragies; Hors 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 735 KB

## Abstract The inhibition of integrin function is a major challenge in medicinal chemistry. Potent ligands are currently in different stages of clinical trials for the antiangiogenic therapy of cancer and age‐related macula degeneration (AMD). The subtype α5β1 has recently been drawn into the focu

Design of peptide oxytocin antagonists w
✍ Maurice Manning; Ling Ling Cheng; Stoytcho Stoev; Nga Ching Wo; W. Y Chan; Hazel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

The peptide oxytocin (OT) antagonist atosiban, approved for tocolytic use in Europe (under the tradename Tractocile), represents an important new therapeutic advance for the treatment of premature labor. This paper presents some new peptide OT antagonists which offer promise as superior tocolytics.